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Abstract: Vildagliptin is a new oral antidiabetic agent that enhances pancreatic islet cell 
responsiveness to glucose. An extensive clinical program involving approximately 22,000 
patients and 7000 patient-years of exposure to vildagliptin has shown that the agent is well 
tolerated and efﬁ  cacious in improving glycemic control in patients with type 2 diabetes mellitus 
(T2DM). Monotherapy trials have shown that signiﬁ  cant HbA1c lowering is accompanied by 
body weight-neutral and lipid-neutral effects, low risk of edema, and low risk of hypoglycemia. 
These characteristics make vildagliptin a favorable partner for combination therapy. Studies of 
vildagliptin as an add-on to metformin have shown signiﬁ  cant improvements in glycemic control 
(comparable to that of thiazolidinedione add-on), with the combination being well tolerated and 
associated with low risks for hypoglycemia and adverse effects on weight or lipid levels. Good 
tolerability and clinically relevant improvements in glycemic control have also been observed 
with vildagliptin as an add-on treatment to sulfonylurea, thiazolidinedione, or insulin treatment 
or in initial combination treatment with pioglitazone. Improved β-cell function and glycemic 
control have been shown with vildagliptin in subjects with impaired glucose tolerance and 
in T2DM patients with mild hyperglycemia, with some evidence in the latter suggesting the 
potential for modifying disease course.
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Type 2 diabetes mellitus (T2DM) is a dual disease, characterized by islet (beta- and 
alpha-) cell dysfunction in the setting of insulin resistance. Moreover, ample clinical 
evidence, such as data from the landmark UK Prospective Diabetes Study (UKPDS), 
indicates that loss of beta-cell function is progressive. This progressive decline leads 
to the clinical impression of failure of therapy in T2DM patients and is the main reason 
why so many patients with T2DM are not within target ranges of glycemic control. 
Moreover, the clear alpha-cell dysfunction that is also present in T2DM has been 
disregarded in previous years, mainly because therapeutic interventions were lacking. 
The need to address this underlying islet cell deﬁ  cit led to a search for therapeutic 
alternatives and has led to the rediscovery of the incretin hormones and their role in 
glucose homeostasis. Improved understanding of their potential has led in turn to the 
development of incretin analogs and incretin enhancers for treatment of T2DM (Deacon 
2004; Vilsbøll and Holst 2004; Drucker 2006; Deacon et al 2008).
The present review will discuss the data available on the incretin enhancer 
vildagliptin, a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4), the 
enzyme responsible for the rapid degradation of the incretin hormones glucagon-
like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). This 
activity increases levels of active incretins and enhances pancreatic islet α- and β-cell 
responsiveness to glucose, thus improving insulin secretion and reducing inappropriate 
glucagon production, improving insulin sensitivity, improving postprandial lipid and Vascular Health and Risk Management 2008:4(6) 1350
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lipoprotein metabolism, and reducing fasting and prandial 
glucose and HbA1c (Ahrén et al 2004; Ahrén et al 2005; 
Mari et al 2005; Burkey et al 2006; D’Alessio et al 2006; 
Matikainen et al 2006; Balas et al 2007; He et al 2007a; Vella 
et al 2007; Azuma et al 2008; Deacon et al 2008). Finally, we 
will discuss the best position for this drug in our therapeutic 
arsenal to address glycemic control in T2DM patients.
Vildagliptin: clinical program
Most data available on vildagliptin until now have come 
from company-sponsored studies designed for registration 
purposes. The drug has been evaluated in an extensive, 
ongoing clinical program, involving approximately 22,000 
treated patients overall and 14,200 vildagliptin-treated 
patients representing approximately 7000 subject-years of 
vildagliptin exposure as of April 2008 (data on ﬁ  le, Novartis). 
It is currently approved for use in treatment of T2DM in the 
European Union, Latin America (Brazil, Mexico), and Asia 
(Korea, Singapore, Philippines). As reviewed herein, clinical 
trials have shown that vildagliptin improves glycemic control 
in patients with T2DM as monotherapy (Pi-Sunyer et al 2007; 
Dejager et al 2007; Rosenstock et al 2007a; Schweizer et al 
2007; Pan et al 2008) and as add-on or initial combination 
therapy with other oral antidiabetic agents and insulin 
(Bosi et al 2007a; Fonseca et al 2007; Garber et al 2007; 
Rosenstock et al 2007b; Bolli et al 2008; Garber et al 2008), 
as well as in patients with impaired glucose tolerance (IGT) 
(Rosenstock et al 2008; Utzschneider et al 2008). Recent 
evidence from T2DM patients with mild hyperglycemia indi-
cates that vildagliptin attenuates deterioration of β-cell func-
tion over long-term treatment (Mari 2008; Scherbaum 2008a; 
Scherbaum 2008b). Vildagliptin treatment is characterized 
by weight-neutral and lipid-neutral effects, very low risk of 
edema, and very low risk of hypoglycemia.
T2DM is characterized by continual loss of glycemic 
control despite treatment, with few patients achieving and 
maintaining treatment goals and combination treatment 
typically becoming unavoidable (UKPDS 1998; Saydah 
2004; Kahn 2006). Current guidelines encourage a prompt 
move to combination treatment when initial metformin 
treatment fails to achieve glycemic goals (Nathan et al 2006). 
The primary utility of vildagliptin is likely to be as add-on 
treatment or in initial combination with metformin. These 
agents have complementary effects in improving glycemic 
control, potential mechanistic synergy, and a favorable 
interaction of tolerability proﬁ  les, including absence of risk 
for weight gain, edema, and hypoglycemia. In the European 
Union, vildagliptin (Galvus®) is approved for use at 50 mg 
bid in combination with metformin or a thiazolidinedione 
and at 50 mg qd in combination with a sulfonylurea (SU). 
A ﬁ  xed-dose vildagliptin/metformin combination is approved 
for use in 50 mg/850 mg and 50 mg/1000 mg formulations.
Pharmacologic overview
Vildagliptin is rapidly absorbed after oral administration, 
with approximately dose-proportional pharmacokinetics 
(He 2007b; He 2007c). No dosage adjustment is necessary 
based on age, gender, body mass index (BMI), food intake, 
presence of hepatic impairment, or concomitant use of com-
monly used drugs (He et al 2008a; He et al 2007d; He et al 
2007e; He et al 2007f; Sunkara 2007; He et al 2008b). Bio-
equivalence of the ﬁ  xed-dose combination of vildagliptin 
and metformin with the individual components has been 
shown; the effect of food in decreasing metformin exposure 
was smaller with the metformin component in the ﬁ  xed-dose 
combination than has been reported with metformin alone, 
and the ﬁ  xed-dose combination can thus be administered 
in the same manner as metformin alone (He et al 2008c; 
He et al 2008d).
Vildagliptin monotherapy trials
Vildagliptin has been evaluated as monotherapy in treatment-
naïve T2DM patients in randomized, double-blind dose-
ranging and comparative trials, including comparisons with 
metformin, rosiglitazone, and acarbose; in subjects with 
impaired glucose tolerance; and in T2DM patients with mild 
hyperglycemia.
Dose-ranging studies
In one dose-ranging study, 354 patients (HbA1c 7.5%–10.0%, 
baseline average 8.4%) were randomized to vildagliptin 
50 mg qd (n = 88), 50 mg bid (n = 83), or 100 mg qd 
(n = 91) or to placebo (n = 92) for 24 weeks (Pi-Sunyer 
2007). Placebo-subtracted mean changes from baseline in 
HbA1c were 0.5%, 0.7%, and 0.9%, respectively, in the 
three vildagliptin dose groups (all p   0.01 vs placebo). 
Placebo-subtracted reductions from baseline fasting plasma 
glucose (FPG; baseline average 10.5 mmol/L) were 0.6, 
1.3, and 1.3 mmol/L, respectively (p   0.001 for latter 
two dose groups). Adverse events occurred with similar 
frequency with vildagliptin (55.8%–59.3%) and placebo 
(57.6%). There was no signiﬁ  cant change in weight, and 
no episodes of hypoglycemia occurred with vildagliptin 
treatment. In a second dose-ranging study, 632 patients 
(HbA1c 7.5%–11.0%, baseline 8.4%) were randomized to 
vildagliptin 50 mg qd (n = 163), 50 mg bid (n = 152), or Vascular Health and Risk Management 2008:4(6) 1351
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100 mg qd (n = 157) or to placebo (n = 160) for 24 weeks 
(Dejager et al 2007). Changes in HbA1c from baseline 
were −0.3% with placebo vs −0.8%, −0.8%, and −0.9% with 
vildagliptin 50 mg qd, 50 mg bid, and 100 mg qd, respectively 
(p   0.01 for all). Body weight decreased by 0.3–1.8 kg 
across all groups. Mild hypoglycemia occurred in 2 patients 
(1.2%) receiving vildagliptin 50 mg qd, in 1 patient (0.6%) 
receiving 100 mg qd, and in none of the patients receiving 
50 mg bid or placebo.
Comparison with metformin
In a noninferiority trial, 780 patients (HbA1c 7.5%–11.0%, 
average 8.7%) were randomized to vildagliptin 50 mg bid 
(n = 526) or metformin 1000 mg bid (n = 254) for 52 weeks 
(Schweizer et al 2007). Mean changes in HbA1c were −1.0% 
with vildagliptin (p   0.001) and −1.4% with metformin 
(p   0.001), with the criterion for noninferiority not being 
met by vildagliptin. In patients with baseline HbA1c  8% 
(mean ∼7.6%), mean changes at 24 weeks were similar with 
vildagliptin (−0.6%, n = 180) and metformin (−0.7%, n = 79). 
In an extension study, where patients were on treatment for 
2 years, HbA1c reductions were sustained at −1.0% with 
vildagliptin (n = 243) and −1.5% with metformin (n = 136) 
(data on ﬁ  le, Novartis).
Over 52 weeks, there was no significant change in 
body weight with vildagliptin and a 1.9-kg weight loss 
with metformin (p   0.001), and hypoglycemia occurred 
in 0.6% of vildagliptin patients and 0.4% of metformin 
patients. Adverse events were similar in frequency with 
vildagliptin (70.1%) and metformin (75.4%), but vildagliptin 
was associated with signiﬁ  cantly fewer gastrointestinal (GI) 
adverse events (22% vs 44%, p   0.001). Among patients 
with diastolic blood pressure (DBP)  90 mmHg (vildagliptin, 
n = 89; metformin, n = 53; baseline 94 mmHg) or systolic 
blood pressure (SBP)  140 mmHg (vildagliptin, n = 150; 
metformin, n = 84; baseline 149–150 mmHg), vildagliptin 
was associated with a signiﬁ  cantly greater decrease in DBP 
(7.5 vs 4.2 mmHg, p   0.05) and SBP (9.1 vs 5.3, p   0.05) 
(Bosi 2 et al 007b).
Comparison with rosiglitazone
In a noninferiority trial, 786 patients (HbA1c 7.5%–11.0%, 
mean ∼8.7%) were randomized to vildagliptin 50 mg 
bid (n = 519) or rosiglitazone 8 mg qd (n = 267) for 24 weeks 
(Rosenstock et al 2007a). Mean changes in HbA1c from 
baseline were −1.1% with vildagliptin vs –1.3% with 
rosiglitazone, with vildagliptin meeting the noninferiority 
criterion. Among patients with baseline HbA1c   9.0% 
(vildagliptin, n = 166; rosiglitazone, n = 88; mean ∼10.0%), 
mean reductions were 1.8% vs 1.9%. Overall, vildagliptin 
was associated with a 0.3-kg reduction in body weight, vs 
a 1.6-kg increase with rosiglitazone (p   0.001); among 
patients with baseline BMI   35 kg/m2 (vildagliptin, n = 132; 
rosiglitazone, n = 76; body weight 111–112 kg), vildagliptin 
patients lost 1.1 kg, compared with a gain of 1.7 kg with 
rosiglitazone (p   0.001). The frequency of adverse events 
was similar in the two groups (61.4% and 64.0%), and one 
case of mild hypoglycemia occurred in each group. Periph-
eral edema was reported in 2.1% of vildagliptin patients and 
4.1% of rosiglitazone patients. Changes in atherogenic lipids 
consisted of small decreases with vildagliptin and moderate 
increases with rosiglitazone in triglycerides (p = 0.01), total 
cholesterol (p   0.003), and LDL cholesterol (p   0.003), 
with a greater increase in HDL cholesterol occurring with 
rosiglitazone (p   0.003).
Comparison with acarbose
In a noninferiority trial, 661 patients (HbA1c 7.5%–11.0%, 
mean ∼8.6%) were randomized to vildagliptin 50 mg bid 
(n = 441) or acarbose up to 100 mg tid (n = 220) for 24 weeks 
(Pan et al 2008). Mean changes in HbA1c were 1.4% with 
vildagliptin and 1.3% with acarbose, with vildagliptin 
meeting the noninferiority criterion. Among patients with 
baseline HbA1c  9.0% (vildagliptin, n = 146; acarbose, 
n = 63; mean ∼9.8%), reductions were 2.0% and 2.1%, 
respectively. Body weight decreased by 0.4 kg with vilda-
gliptin and by 1.7 kg with acarbose (p   0.001). Adverse 
events occurred in 35% of vildagliptin patients and in 51% of 
acarbose patients, with a signiﬁ  cant reduction in GI adverse 
events with vildagliptin (12.3% vs 25.5%, p   0.001). No 
hypoglycemia occurred in either group.
Impaired glucose tolerance
In a randomized, double-blind trial, 179 subjects with IGT 
(2-h glucose 9.1 mmol/L, HbA1c 5.9%) were randomized 
to vildagliptin 50 mg qd (n = 90) or placebo (n = 89) for 
12 weeks (Rosenstock et al 2008). Compared with placebo, 
vildagliptin signiﬁ  cantly increased levels of GLP-1 and GIP 
and reduced glucagon levels. Postprandial insulin levels 
were unaffected, and vildagliptin treatment was associated 
with a signiﬁ  cant reduction in prandial glucose excursion 
(incremental area under the curve [AUC] −1.0 mmol/L/h, 
p   0.001), representing a 32% reduction vs placebo. β-cell 
function, assessed by insulin secretory rate (ISR) relative to 
glucose measured as ISR AUC0–2 h/glucose AUC0–2 h, was 
signiﬁ  cantly increased (+6.4 pmol/min/m2/mM, p = 0.002) Vascular Health and Risk Management 2008:4(6) 1352
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with vildagliptin. Adverse event proﬁ  les were similar for 
vildagliptin and placebo. No cases of hypoglycemia were 
reported. Change in body weight was −0.6 kg with vilda-
gliptin and −0.1 kg with placebo.
Mild hyperglycemia
A total of 306 patients with T2DM and mild hyperglyce-
mia (HbA1c 6.2%–7.5%) were randomized to vildagliptin 
50 mg qd (n = 156) or placebo (n = 150) for 52 weeks 
followed by a 4-week washout period (Mari et al 2008; 
Scherbaum et al 2008a). At baseline, HbA1c and FPG 
were 6.7% and 7.1 mmol/L, respectively, in the vildagliptin 
group and 6.8% and 7.2 mmol/L, respectively, in the pla-
cebo group. At 52 weeks, changes in HbA1c were −0.2% 
with vildagliptin vs +0.1% with placebo (between-group 
difference p   0.001); FPG did not change signiﬁ  cantly 
with vildagliptin (+0.2 mmol/L) and increased with pla-
cebo (+0.5 mmol/L, p   0.001; between-group difference 
p = 0.032). Compared with patients on placebo, vildagliptin 
patients had a signiﬁ  cant reduction in 2-hour postpran-
dial glucose (−0.9 mmol/L, p = 0.012) and signiﬁ  cantly 
improved β-cell function assessed as ISR AUC0–2 h/glucose 
AUC0–2 h (+5.0 pmol/min/m2/mM, p   0.001) (Scherbaum 
et al 2008a).
Additional characterization of the effect of vildagliptin on 
model-assessed β-cell function (Mari 2008) showed that the 
0.3% reduction in HbA1c and signiﬁ  cantly reduced glucose 
AUC0–2  h (−1.7 mM/h, p = 0.002) were accompanied by signif-
icantly increased fasting insulin secretory tone (+34.1 pmol/
min/m2, p   0.001), glucose sensitivity (+20.7 pmol/min/m2/
mM, p   0.001), and rate sensitivity (163.6 pmol/m2/mM, 
p = 0.015), with total insulin secretion (ISR AUC0–2 h) and a 
potentiation factor (expressing relative potentiation of insu-
lin secretory response to glucose) during meals remaining 
unchanged. Body weight decreased by 0.5 kg with vilda-
gliptin and by 0.2 kg with placebo. Adverse events were 
similar in the two groups; hypoglycemia occurred in none of 
the vildagliptin patients and in one placebo patient.
After this study of 52 weeks, a washout period of 4 weeks 
was built in, followed by continuation of therapy in a sub-
group of patients (n = 131). None of the effects of vildagliptin 
treatment at 52 weeks were present after the 4-week washout 
period, suggesting absence of a potential disease-modifying 
effect over 1 year of treatment. The potential for such an 
effect is suggested by preclinical studies showing that GLP-1, 
incretin mimetics, and DPP-4 inhibitors inhibit apoptosis, 
augment β-cell function, and increase β-cell mass in rodent 
models with a high rate of β-cell turnover (Baggio and 
Drucker 2006). However, results of the 52-week extension 
after the 4-week washout following the core 52-week study 
(total 104 treatment weeks and 4 weeks washout period) sug-
gest that vildagliptin treatment may attenuate deterioration 
of β-cell function over 2 years of treatment in mild hyper-
glycemia (Scherbaum et al 2008b). Among the 131 patients 
in the extension study (vildagliptin, n = 68; placebo, n = 63), 
vildagliptin patients had a signiﬁ  cant reduction vs placebo in 
HbA1c after the second 52-week treatment period (−0.5%, 
p = 0.008). Placebo-adjusted changes from core study 
baseline values in FPG, glucose AUC0–2 h, and ISR AUC0–2 h/
glucose AUC0–2 h tended to be greater after 2 years than after 
1 year of vildagliptin treatment. After the second washout 
period (week 112), the placebo-adjusted change from week 0 
to week 112 in ISR AUC0–2 h/glucose AUC0–2 h was 3.2 pmol/
min/m2/mM (p = 0.058) and the placebo-adjusted change in 
HbA1c was −0.3% (p = 0.051), indicating an attenuated rate 
of loss of glycemic control in the absence of active treatment. 
Adverse events were similar in the two groups; two placebo 
patients and no vildagliptin patients had hypoglycemia. 
Body weight did not change signiﬁ  cantly in placebo patients 
(–0.3 kg) and decreased signiﬁ  cantly in vildagliptin patients 
(−1.1 kg, p = 0.026) compared with core study baseline.
Summary of pooled monotherapy results
Pooled 24-week data from monotherapy arms (data on 
ﬁ  le, Novartis) show that vildagliptin is effective across 
the range of levels of hyperglycemia and baseline BMI 
values and in older and younger patients. For all patients 
receiving 50 mg bid (n = 1569), change in HbA1c from 
baseline was −1.0%, including changes of −0.6% in those 
with baseline HbA1c   8.0% (n = 543), −0.9% for base-
line HbA1c   8.0–9.0% (n = 490), −1.6% for baseline 
HbA1c   9.0%–10.0% (n = 362), and −1.9% for baseline 
HbA1c   10.0% (n = 174) (p   0.001 for all compared with 
baseline). Reductions from baseline HbA1c (8.6%–8.7%) 
according to BMI with vildagliptin 50 mg bid were 1.1% 
and 0.9% for  30 kg/m2 (n = 819) and  30 kg/m2 (n = 748), 
respectively, and 1.1% and 1.0% for   35 kg/m2 (n = 1202) 
and  35 kg/m2 (n = 365), respectively (p   0.001 for all vs 
baseline). Reductions with 50 mg bid were 1.1% in both 
patients aged  65 years (n = 1326, baseline 8.7%) and those 
aged  65 years (n = 243, baseline 8.4%).
Changes in fasting lipids with vildagliptin treatment were 
minor, consisting of reductions of 0.6%, 2.7%, and 2.0% in 
triglycerides, total cholesterol, and LDL cholesterol, respec-
tively, and an increase of  3.9% in HDL cholesterol at the 50 mg 
bid dose. Rates of peripheral edema were similar to that seen Vascular Health and Risk Management 2008:4(6) 1353
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with placebo, consisting of 0.9% with vildagliptin 50 mg 
qd (n = 655), 1.3% with vildagliptin 50 mg bid (n = 2251), 
2.0% with metformin up to 2000 mg/d (n = 252), 4.1% with 
rosiglitazone 8 mg/d (n = 267), 7.9% with pioglitazone 
30 mg/d (n = 216, in a monotherapy arm in a combination 
study discussed below), and 1.2% with placebo (n = 586). 
There was a low risk of hypoglycemia, and rates of other 
clinical adverse events were comparable to those seen with 
placebo (Table 1).
Combination therapy
Vildagliptin has been assessed in randomized, double-blind 
trials as add-on therapy to metformin, SU, thiazolidinedi-
one, and insulin treatment and in initial combination with 
pioglitazone.
Vildagliptin as add-on to metformin
Add-on to metformin vs placebo
A total of 544 patients with inadequate glycemic control 
(HbA1c 7.5%–11.0%; mean 8.3%–8.4%) on a metformin 
regimen of  1500 mg/d were randomized to vildagliptin 
50 mg qd (n = 177) or 50 mg bid (n = 185) or placebo 
(n = 182) while continuing on metformin for 24 weeks; 
metformin in all patients was titrated up to  2000 mg/d 
by study baseline, and the mean study dose was 2100 mg/d 
(Bosi et al 2007a). HbA1c was reduced by a mean of 0.7% 
with the addition of vildagliptin 50 mg qd and by 1.1% with 
vildagliptin 50 mg bid compared with metformin/placebo 
(both p   0.001) (Figure 1). FPG (baseline 9.7–10.1 mmol/L) 
was reduced by 0.8 mmol/L (p = 0.003) and 1.7 mmol/L 
(p   0.001), respectively, with vildagliptin 50 mg qd and 
bid. In predeﬁ  ned analyses, the addition of   vildagliptin 
50 mg bid produced changes in HbA1c vs metformin/placebo 
of  −1.3% vs −0.2% in patients aged  65 years (vildagliptin, 
n = 20; metformin/placebo, n = 22; baseline ∼8.3%), −0.8% 
vs +0.2% in those with baseline BMI   30 kg/m2 (vilda-
gliptin, n = 103; metformin/placebo, n = 86; baseline ∼8.3%), 
and −1.3% vs 0.0% in those with baseline HbA1c  9.0% 
(vildagliptin, n = 29; metformin/placebo, n = 29) (data on ﬁ  le, 
Novartis). The HbA1c target of  7.0% was reached in 
54% of vildagliptin 50 mg bid patients, 50% of vildagliptin 
50 mg qd patients, and 14% of metformin/placebo patients 
starting treatment with HbA1c  8.0% and in 31%, 22%, and 
13%, respectively, of those starting at HbA1c   8.0%–8.5% 
(Bosi et al 2007a). Improved β-cell function with the addi-
tion of vildagliptin was shown by signiﬁ  cant increases 
in adjusted mean ISR AUC0–2 h/glucose AUC0–2 h with 
vildagliptin qd (n = 53; +6.9 pmol/min/m2/mM) and 
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bid (n = 57; +7.3 pmol/min/m2/mM) vs metformin/placebo 
(n = 54; +1.6 pmol/min/m2/mM; p   0.001 for both compari-
sons); adjusted mean changes in 2-hour postprandial glucose 
were −1.9, –2.3, and –0.1 mmol/L, respectively (p   0.001 
for both vs metformin/placebo) (Bosi et al 2007a) (data on 
ﬁ  le, Novartis).
There were no signiﬁ  cant changes in body weight from 
baseline (mean 93–95 kg) with vildagliptin qd (−0.4 kg) or 
bid (+0.2 kg) and a signiﬁ  cant decrease with metformin/
placebo (–1.0 kg, p   0.001) (Bosi et al 2007). Among 
patients with baseline DPB   90 mmHg and SBP   140 
mmHg (vildagliptin 50 mg bid, n = 57; metformin/placebo, 
n = 59), reductions in DBP were −4.0 mmHg with vilda-
gliptin 50 mg bid (p   0.05) and −0.9 mmHg with met-
formin/placebo (p = NS) and reductions in SBP were −9.8 
(p   0.05) and −6.3 (p   0.05), respectively. Vildagliptin 
had a neutral effect on fasting lipids; changes for vildagliptin 
qd, vildagliptin bid, and metformin/placebo were, respec-
tively, +1.0% (p = 0.014 vs metformin/placebo), +4.8%, and 
+18.4% for triglycerides; −1.6%, −1.8%, and +1.7% for total 
cholesterol; +0.4%, +1.8%, and +0.7% for LDL cholesterol; 
and −0.6%, +0.2%, and +2.0% for HDL cholesterol. Adverse 
events occurred with similar frequency in all treatment groups 
(63.3%–65.0%), with GI adverse events occurring in 9.6% 
of patients (p = 0.022 vs metformin/placebo) on vildagliptin 
qd, 14.8% of those on vildagliptin bid, and 18.2% of those 
on metformin/placebo. Mild hypoglycemia occurred in one 
patient in each group (0.6% with vildagliptin qd, 0.5% with 
vildagliptin bid, and 0.6% with metformin/placebo).
Add-on to metformin vs pioglitazone 
add-on
In a noninferiority trial, 576 patients with inadequate 
glycemic control (HbA1c 7.5%–11.0%; mean ∼8.4%) 
on stable metformin  1500 mg/d were randomized to 
vildagliptin 50 mg bid (n = 295) or pioglitazone 30 mg 
qd (n = 281) plus continued metformin for 24 weeks; the 
metformin dose was titrated up to  2000 mg/d by study 
baseline, and the average study dose was approximately 
2000 mg/d (Bolli et al 2008). Adjusted mean changes 
in HBA1c were −0.9% with vildagliptin vs −1.0% with 
pioglitazone, with vildagliptin meeting the noninferiority crite-
rion (Figure 2). Among patients with baseline HbA1c  9.0% 
(vildagliptin, n = 63; pioglitazone, n = 58; baseline ∼9.7%), 
HbA1c was reduced by 1.5% in both groups. FPG (baseline 
mean ∼11.0 mmol/L) was reduced by adjusted means of 
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Figure 1 Mean HbA1c ± SE in patients receiving vildagliptin qd or bid or placebo as an add-on to metformin therapy ( 1500 mg/d). Reproduced with permission from Bosi E, 
Camisasca RP, Collober C, et al 2007a. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes 
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1.4 mmol/L with vildagliptin and 2.1 mmol/L with pioglitazone, 
with vildagliptin not meeting the noninferiority criterion. The 
latter ﬁ  nding reﬂ  ects differences in mechanism of action of 
the two agents: insulin-sensitizing thiazolidinediones have 
more of an effect during fasting, whereas vildagliptin exerts its 
glucose-dependent effect in the postprandial period. Change in 
body weight among all patients (baseline ∼91 kg) was +0.3 kg 
with vildagliptin vs +1.9 kg with pioglitazone (p   0.001); 
the change among patients with baseline BMI   35 kg/m2 
(vildagliptin, n = 73; pioglitazone, n = 70, baseline ∼110 kg) 
was +0.1 kg with vildagliptin vs +2.6 kg with pioglitazone 
(p   0.001). Adverse events occurred with similar frequency 
in the vildagliptin and pioglitazone groups (56.4% and 60.0%, 
respectively). Surprisingly, an unusually high frequency of 
peripheral edema was reported in vildagliptin patients (8.8%, 
vs 6.1% with pioglitazone); this ﬁ  nding may reﬂ  ect the speciﬁ  c 
criteria used for identifying edema in the study and/or the much 
greater frequency of edema in vildagliptin patients receiving 
calcium channel blocker therapy vs no edema in pioglitazone 
patients receiving such concomitant treatment. In another 
study of initial combination therapy with pioglitazone and 
vildagliptin, which contained monotherapy arms, peripheral 
edema was reported in 9.3% of the pioglitazone monotherapy 
group, 5.2% of the vildagliptin monotherapy group, and 6.1% 
of the combination therapy group (Bolli et al 2007). Mild 
hypoglycemia occurred in one vildagliptin patient and in none 
of the pioglitazone patients.
Combination with other antidiabetic drugs
Add-on to SU vs placebo
A total of 515 patients with inadequate glycemic control on 
SU monotherapy (HbA1c 7.5%–11.0%; mean 8.5%–8.6%) 
were randomized to vildagliptin 50 mg qd (n = 170) or 50 mg 
bid (n = 169) or placebo (n = 176) plus glimepiride 4 mg qd 
for 24 weeks (Garber 2008). Placebo-subtracted reductions 
in HbA1c were 0.6% with vildagliptin qd and 0.7% with 
vildagliptin bid (both p   0.001). Although both reductions 
were signiﬁ  cant, there was no dose response observed with 
the higher vildagliptin dose; vildagliptin is approved for use 
in combination with an SU at 50 mg qd. Changes in patients 
with baseline HbA1c   9.0% (vildagliptin qd, n = 32; 
glimepiride/placebo, n = 4; baseline 9.8%) were −1.0% with 
vildagliptin 50 mg qd and 0.0% with glimepiride/placebo; 
changes in patients aged  65 years (vildagliptin qd, n = 41; 
glimepiride/placebo, n = 38; baseline 8.5%) were −0.7% 
and +0.1%, respectively. Adverse events were similar in 
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frequency with vildagliptin 50 mg qd and with glimepiride/
placebo (67.1% and 64.2%, respectively). Hypoglycemia 
occurred in two patients (1.2%) receiving vildagliptin 50 mg 
qd and one patient (0.6%) receiving glimepiride/placebo. 
Body weight decreased slightly with both treatments (−0.1 kg 
and −0.4 kg).
Add-on to pioglitazone vs placebo
A total of 463 patients with inadequate glycemic control 
on thiazolidinedione treatment (HbA1c 7.5%–11.0%, mean 
8.6%–8.7%) were randomized to vildagliptin 50 mg qd 
(n = 147) or 50 mg bid (n = 158) or to placebo (n = 158) 
plus maximum-dose pioglitazone at 45 mg qd for 24 weeks 
(Garber et al 2007). Changes in HbA1c were −0.8% with 
vildagliptin qd and −1.0% with vildagliptin bid, vs −0.3% 
with pioglitazone/placebo (p   0.001 for both comparisons). 
Adverse events were similar in frequency in all groups 
(48.7%–55.5%). Mild hypoglycemia occurred in none of 
the patients with vildagliptin qd, in one patient (0.6%) with 
vildagliptin bid, and in 3 patients (1.9%) with pioglitazone/
placebo. Body weight increased by 1.4 kg with placebo/
pioglitazone and by an additional 0.1 kg with vildagliptin qd 
and an additional 1.3 kg with vildagliptin bid (p = 0.003 vs 
placebo/pioglitazone). No consistent or dose-related changes 
in lipids were observed with the addition of vildagliptin to 
pioglitazone.
Add-on to insulin vs placebo
A total of 296 patients with inadequate glycemic control on 
insulin (HbA1c 7.5%–11.0%, baseline ∼8.4%, mean dura-
tion of insulin use ∼6 years) received vildagliptin 50 mg 
bid (n = 144) or placebo (n = 152) plus ongoing insulin 
for 24 weeks; the mean daily insulin dose at baseline was 
81.2–81.9 U, and dose adjustments were permitted during the 
study (Fonseca 2007). The change in insulin dose was +1.2 U 
in the vildagliptin group and +4.1 U in the insulin/placebo 
group. Changes in HbA1c were −0.5% with vildagliptin 
and −0.2% with insulin/placebo (p = 0.01); among patients 
aged  65 years (vildagliptin, n = 42; insulin/placebo, n = 41; 
baseline 8.4%), changes were −0.7% with vildagliptin add-on 
and −0.1% with insulin/placebo. Vildagliptin was associated 
with signiﬁ  cant reductions in number of hypoglycemic epi-
sodes (113 vs 185, p   0.001) and number of severe events 
(0 vs 6, p   0.05). The change in body weight was +1.3 kg 
in vildagliptin/insulin patients and +0.6 kg in insulin/placebo 
patients.
In an extension of this trial, 96 patients on vilda-
gliptin 50 mg bid continued on treatment and 104 in the 
insulin/placebo group switched to vildagliptin 50 mg qd 
plus ongoing insulin for an additional 28 weeks (total 
52 weeks) (Fonseca et al 2008). During the extension phase, 
the average insulin dose increased by approximately 2 U. At 
52 weeks, the efﬁ  cacy of vildagliptin 50 mg bid in reduc-
ing HbA1c was maintained (−0.5%); in patients receiving 
vildagliptin 50 mg qd, the change between week 24 and week 
52 was −0.4%. In patients aged  65 years receiving 50 mg 
bid, the change in HbA1c at 52 weeks was −0.9%, compared 
with −0.24% in younger patients, indicating that overall 
efﬁ  cacy primarily reﬂ  ected the effect in older patients. There 
was no signiﬁ  cant change in body weight with continued 
50 mg bid treatment (+0.3 kg during the extension; +1.8 kg 
over 52 weeks) or during the extension in patients switched 
to 50 mg qd (+0.5 kg). The rate of hypoglycemic events per 
patient-year was 1.80 in the 50 mg bid group and 1.78 in the 
50 mg qd group, compared with 2.66 in the insulin/placebo 
group during the core study; in the elderly patients, event 
rates were 2.1 and 2.3 in the vildagliptin groups, compared 
with 3.3 in insulin/placebo patients during the core study.
Initial combination with pioglitazone
A total of 607 treatment-naïve patients (HbA1c 7.5%−11.0%, 
mean ∼8.7%) were randomized to vildagliptin 100 mg qd 
(n = 154), pioglitazone 30 mg qd (n = 161), vildagliptin 
50 mg qd plus pioglitazone 15 mg qd, or vildagliptin 100 mg 
qd plus pioglitazone 30 mg qd for 24 weeks (Rosenstock 
et al 2007b). Changes in HbA1c were −1.1% with vilda-
gliptin alone, −1.4% with pioglitazone alone, −1.7% with the 
50 mg/15 mg combination (p   0.05 vs pioglitazone alone), 
and −1.9% with the 100 mg/30 mg combination (p   0.001 
vs pioglitazone alone). The target HbA1c level of  7.0% was 
achieved in 43%, 43%, 54%, and 65% of patients, respec-
tively (p   0.001for the 100 mg/30 mg combination vs both 
monotherapy groups). Among patients with baseline HbA1c 
  9.0% (average ∼10.0%), reductions were 1.5% with vilda-
gliptin alone (n = 46), 1.8% with pioglitazone alone (n = 54), 
2.3% with the 50 mg/15 mg combination (n = 49), and 2.8% 
with the 100 mg/30 mg combination (n = 54) (p   0.001 for 
the higher-dose combination vs pioglitazone alone). Among 
patients aged  65 years, reductions were 1.3% with vilda-
gliptin alone (n = 17), 1.2% with pioglitazone alone (n = 19), 
1.7% with the 50 mg/15 mg combination (n = 15), and 2.3% 
with the 100 mg/30 mg combination (n = 21) (p   0.001 for 
the higher-dose combination vs pioglitazone alone). Changes 
in body weight (mean 80–82 kg) were +0.2 kg with vilda-
gliptin monotherapy, +1.5 kg with pioglitazone monotherapy, 
+1.4 kg with the 50 mg/15 mg combination, and +2.1 kg with Vascular Health and Risk Management 2008:4(6) 1357
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the 100 mg/30 mg combination. Adverse event rates were 
comparable in all groups (45.8%–51.6%). Rates of edema 
were 5.2% with vildagliptin alone, 9.3% with pioglitazone 
alone, 3.5% with the 50 mg/15 mg combination, and 6.1% 
with the 100 mg/30 mg combination. Hypoglycemia occurred 
in one patient (0.7%) receiving vildagliptin monotherapy and 
in one (0.7%) receiving the 100 mg/30 mg combination.
Summary of pooled combination
study adverse events
Pooled adverse event data from vildagliptin combination 
studies, shown in Table 2, indicate good tolerability with 
vildagliptin in combination with other antidiabetic agents.
Discussion and conclusion
The availability of a new class of agents in our therapeutic 
toolkit for the treatment of hyperglycemia in T2DM is of 
great importance to reduce the burden of diabetes. In the new 
group of inhibitors of DPP-4, vildagliptin proves to be a very 
efﬁ  cacious drug for improving glycemic control in a wide 
range of T2DM patients, ranging from the IGT population 
to patients with advanced disease on insulin. Its potential for 
lowering HbA1c is in the range of that of thiazolidinediones 
and acarbose in monotherapy, and sustained efﬁ  cacy for up 
to 2 years has been demonstrated. The effect of improving 
postprandial glycemia provides a good alternative for the up 
till now limited therapeutic options of affecting postprandial 
glycemia excursion. In addition, also fasting glycemia is 
clearly affected by vildagliptin.
Compared to the other gliptins, vildagliptin distinguishes 
itself by behaving like a surrogate substrate, being altered 
itself by the enzyme DPP-4 (Ahrén and Foley 2008). No 
head-to-head comparison clinical trials between the dif-
ferent gliptins are available at present, so that only indirect 
comparisons can be made. HbA1c lowering effects seem to 
be comparable over the spectrum of gliptins, whereas some 
studies indicate a greater reduction of fasting glycemia for 
sitagliptin (Amori et al 2007).
The most interesting combination in which to use vilda-
gliptin is with metformin, for two different reasons. First, 
from a pathogenic perspective, combining an agent primarily 
targeting insulin resistance, like metformin, with an agent 
primarily targeting the β-cell, like vildagliptin, is a logical 
approach. In addition, the choice of vildagliptin gives the 
added value of also targeting the α-cell dysfunction that is 
clearly present in T2DM patients, with insufﬁ  cient suppres-
sion of glucagon secretion leading to postprandial hypergly-
cemia. Second, more than additive effects have been observed 
with this combination. Indeed, metformin has been found to 
increase GLP-1 levels, presumably through increasing GLP-1 
synthesis rather than DPP-4 inhibition (Hinke et al 2002; 
Yasuda et al 2002; Migoya et al 2007). One study found that 
vildagliptin administration in treatment-naïve patients (n = 5) 
resulted in a prandial active GLP-1 level of approximately 
10 pmol/L and that the addition of vildagliptin in metformin-
treated patients (n = 12) resulted in a level more than twice as 
high (p   0.05) (Dunning et al 2006). Based on these reasons, 
the combination of vildagliptin with metformin will be a 
Table 2 Incidence of adverse events ( 5%) in vildagliptin combination trials (pooled data at 24 weeks)
No (%)
Vildagliptin 
50 mg qd (n = 693)
Vildagliptin 
50 mg bid (n = 2343)
Total placebo 
(n = 718)
Total comparatorsa 
(n = 2387)
Any 411 (59.3) 1466 (62.6) 468 (65.2) 1611 (67.5)
Adverse events 
in  5% of patients
  Nasopharyngitis 44 (6.3) 126 (5.4) 41 (5.7) 134 (5.6)
  Dizziness 33 (4.8) 125 (5.3) 43 (6.0) 207 (8.7)
  Headache 34 (4.9) 125 (5.3) 21 (2.9) 114 (4.8)
 Inﬂ  uenza 18 (2.6) 86 (3.7) 40 (5.6) 83 (3.5)
  Asthenia 22 (3.2) 85 (3.6) 28 (3.9) 146 (6.1)
  Tremor 23 (3.3) 85 (3.6) 47 (6.5) 296 (12.4)
   Upper respiratory 
tract infection
32 (4.6) 75 (3.2) 41 (5.7) 77 (3.2)
  Hyperhidrosis 17 (2.5) 73 (3.1) 41 (5.7) 247 (10.3)
aIncludes both active comparators (including insulin) and placebo.
Adapted from Summary of Clinical Safety, 5 December 2007.   Table 4–1c. Novartis Pharmaceuticals, data on ﬁ  le.Vascular Health and Risk Management 2008:4(6) 1358
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treatment of choice in T2DM patients, but ingesting multiple 
pills per day severely hampers patient compliance, espe-
cially in this already polymedicated population. Fixed-dose 
combinations may improve treatment compliance. Studies 
have shown signiﬁ  cantly greater adherence rates (Melikian 
et al 2002; Blonde et al 2003) and improved glycemic 
control (Blonde et al 2003) with a ﬁ  xed-dose combination 
of metformin/glyburide than with a free-drug component 
combination of the two. Investigation of a ﬁ  xed-dose combi-
nation of vildagliptin 50 mg and metformin 1000 mg showed 
equivalent plasma concentrations of both vildagliptin and 
metformin with the ﬁ  xed-dose combination compared with 
the free component combination (He et al 2008c). The ﬁ  xed-
dose vildagliptin/metformin combination in formulations 
of vildagliptin 50 mg/metformin 850 mg and vildagliptin 
50 mg/metformin 1000 mg was recently approved in the 
European Union and may thus be a treatment of choice, even 
early on in the therapy of T2DM patients.
In our efforts to control glucose levels in T2DM patients, 
efﬁ  cacy of the treatment in terms of glucose-lowering poten-
tial is, however, only one aspect of therapy. Side effects, such 
as hypoglycemia and weight gain, or simply overall tolerance 
of the treatment will determine usability. Vildagliptin pres-
ents a very desirable proﬁ  le here, with monotherapy studies 
showing low risk for hypoglycemia, no weight gain, and an 
incidence of edema, gastrointestinal symptoms, and other 
adverse events similar to that seen with placebo.
When combining the data on efﬁ  cacy and on safety, it 
is clear that most T2DM patients with sufﬁ  cient beta-cell 
reserve will beneﬁ  t from therapy with vildagliptin. Especially 
patients where hypoglycemia needs to be avoided at all cost, 
like elderly patients or patients with active professional lives, 
or where weight gain is a major concern, will beneﬁ  t from 
this treatment (Mathieu and Bollaerts 2007). The drug proﬁ  le 
makes it a ﬁ  rst line choice when thinking of a tool to increase 
beta-cell insulin secretion.
Vildagliptin is currently approved in the European Union 
(26 September 2007, European Medicines Agency [EMEA]) 
for use in combination with metformin and thiazolidinediones 
at 50 mg bid and with SU at 50 mg qd, with ﬁ  xed-dose combi-
nations with metformin (50 mg/850 mg and 50 mg/1000 mg) 
also available for use (14 November 2007, EMEA) (Galvus 
EU PI; Eucreas EU PI). Based on observations using higher 
doses than the ones proposed for clinical use, a caution 
for liver dysfunction was built in to the label. Vildagliptin 
should not be used in patients with hepatic impairment. Rare 
cases of hepatic dysfunction have been reported; therefore, 
liver function tests should be performed prior to initiation 
of treatment, at 3-month intervals during the ﬁ  rst year, and 
periodically thereafter.
Whereas vildagliptin may be used throughout the whole 
spectrum of T2DM patients, an interesting observation was 
made in patients where vildagliptin was combined with 
insulin. In these patients, an insulin sparing effect was seen, 
but more interestingly, less hypoglycemia was observed. 
No direct explanation is available, but further exploration 
of this phenomenon is warranted because of great clinical 
importance.
Finally, there remains the promise of beta-cell protection 
in the long term. At present, only theoretical considerations 
and animal data are available, suggesting this will indeed be 
the case for vildagliptin. In clinical trials, long-term data are 
scarce, with 2-year data available only recently (Scherbaum 
et al 2008b) to suggest that in the studied subgroup a change 
in residual beta-cell function was indeed present in patients 
treated with vildagliptin for 2 years.
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